78 related articles for article (PubMed ID: 11480309)
1. Probabilistic cost-effectiveness analysis of HIV prevention. Comparing a Bayesian approach with traditional deterministic sensitivity analysis.
Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
Eval Rev; 2001 Aug; 25(4):474-502. PubMed ID: 11480309
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian approach to net health benefits: an illustration and application to modeling HIV prevention.
Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
Med Decis Making; 2004; 24(6):634-53. PubMed ID: 15534344
[TBL] [Abstract][Full Text] [Related]
3. The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model.
Uthman OA; Popoola TA; Yahaya I; Uthman MM; Aremu O
Value Health; 2011 Jan; 14(1):70-9. PubMed ID: 21211488
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
[TBL] [Abstract][Full Text] [Related]
7. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
9. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
10. Impact of generic drug entry on cost-effectiveness analysis.
Shih YC; Han S; Cantor SB
Med Decis Making; 2005; 25(1):71-80. PubMed ID: 15673583
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of environmental-structural communication interventions for HIV prevention in the female sex industry in the Dominican Republic.
Sweat M; Kerrigan D; Moreno L; Rosario S; Gomez B; Jerez H; Weiss E; Barrington C
J Health Commun; 2006; 11 Suppl 2():123-42. PubMed ID: 17148102
[TBL] [Abstract][Full Text] [Related]
12. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
Spiegelhalter DJ; Best NG
Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
[TBL] [Abstract][Full Text] [Related]
13. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
Zethraeus N; Johannesson M; Jönsson B; Löthgren M; Tambour M
Pharmacoeconomics; 2003; 21(1):39-48. PubMed ID: 12484802
[TBL] [Abstract][Full Text] [Related]
14. Large-sample Bayesian posterior distributions for probabilistic sensitivity analysis.
Hazen GB; Huang M
Med Decis Making; 2006; 26(5):512-34. PubMed ID: 16997928
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.
Westerhout KY; Verheggen BG; Schreder CH; Augustin M
J Med Econ; 2012; 15(5):906-17. PubMed ID: 22533527
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of expanded testing for primary HIV infection.
Coco A
Ann Fam Med; 2005; 3(5):391-9. PubMed ID: 16189054
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
18. Condom distribution: a cost-utility analysis.
Bedimo AL; Pinkerton SD; Cohen DA; Gray B; Farley TA
Int J STD AIDS; 2002 Jun; 13(6):384-92. PubMed ID: 12015012
[TBL] [Abstract][Full Text] [Related]
19. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
[TBL] [Abstract][Full Text] [Related]
20. Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS.
Kamae MS; Kamae I; Cohen JT; Neumann PJ
J Med Econ; 2011; 14(2):187-93. PubMed ID: 21332273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
